Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: A case report

被引:6
|
作者
Shimabukuro-Vornhagen A. [1 ]
Rothe A. [1 ]
Nogova L. [1 ]
Kochanek M. [1 ]
Scheid C. [1 ]
Von Bergwelt-Baildon M. [1 ]
机构
[1] Department i of Internal Medicine, University Hospital Cologne, D-50924 Köln
关键词
Imatinib; Chronic Myeloid Leukemia; International Normalize Ratio; Dasatinib; Fresh Freeze Plasma;
D O I
10.1186/1752-1947-5-215
中图分类号
学科分类号
摘要
Introduction. In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions. Megakaryocytes in such patients have been shown to be derived from the BCR-ABL+ clone, and abnormal platelet function is frequent in chronic myeloid leukemia. However, little is known about the influence of modern targeted therapy on chronic myeloid leukemia-associated platelet disorders. Case presentation. We report the case of a massive hemorrhage in a 32-year-old Caucasian man caused by chronic myeloid leukemia-associated platelet dysfunction, which improved after treatment with imatinib. Conclusion: This report demonstrates that platelet dysfunction and bleeding disorder in BCR-ABL+ chronic myeloid leukemia can successfully be treated with imatinib. We suggest the monitoring of platelet function in future studies using imatinib to treat patients with chronic myeloid leukemia. © 2011 Shimabukuro-Vornhagen et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [41] The biology of chronic myelogenous leukemia: Implications for imatinib therapy
    Alvarez, Ricardo H.
    Kantarjian, Hagop
    Cortes, Jorge E.
    SEMINARS IN HEMATOLOGY, 2007, 44 (01) : S4 - S14
  • [42] Severe aplastic anemia after the use of Imatinib Mesilate for Chronic Myelogenous Leukemia in chronic phase. Report of a case.
    Cliquet, MG
    D'avila, VNB
    Minari, FC
    Carnevalli, EM
    Assis, JR
    Ferro, MC
    BLOOD, 2003, 102 (11) : 324B - 324B
  • [43] Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase
    Warren, E
    Ward, S
    Gordois, A
    Scuffham, P
    CLINICAL THERAPEUTICS, 2004, 26 (11) : 1924 - 1933
  • [44] Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation
    Numata, Ayumi
    Kajiyama, Ryoko
    Itabashi, Megumi
    Ishii, Yoshimi
    Yamamoto, Wataru
    Motohashi, Kenji
    Matsumoto, Kenji
    Hagihara, Maki
    Ishigatsubo, Yoshiaki
    Fujisawa, Shin
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 201 - 202
  • [45] Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count
    Trapp, OM
    Beykirch, MK
    Petrides, PE
    BLOOD CELLS MOLECULES AND DISEASES, 1998, 24 (02) : 9 - 13
  • [46] Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
    Bhatia, R
    Holtz, M
    Niu, N
    Gray, R
    Snyder, DS
    Sawyers, CL
    Arber, DA
    Slovak, ML
    Forman, SJ
    BLOOD, 2003, 101 (12) : 4701 - 4707
  • [47] Bowel Perforation Secondary to Ponatinib Treatment in a Chronic Myelogenous Leukemia Patient: A Case Report
    Sallam, Asma
    Gmati, Giamal Edin
    Salman, Refaat
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [48] Roentgen ray treatment of leukemia - Report of case (Myelogenous typl) with apparent improvement, death, autopsy
    Grosh, LC
    Stone, WJ
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1904, 43 : 0018 - 0022
  • [49] Case report: Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment
    Chung, Hee-Jung
    Chi, Hyun-Sook
    Cho, Young-Uk
    Park, Chan-Jeoung
    Seo, Eul Ju
    Kirn, Kyung-Hee
    Lee, Je-Hwan
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2008, 38 (03): : 283 - 286
  • [50] Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia: What Are They and How Do They Affect Treatment?
    Allen-Bard, Sandra
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2009, 13 (05) : 537 - 542